Research Area: Neurological Disease
Biological Activity:
Latrepirdine (INN, also known as dimebolin and sold as Dimebon), is an antihistamine drug. Research is continuing in both Russia and western nations into potential applications as a neuroprotective drug to combat Alzheimer’s disease and, possibly, as a nootropic as well. However, a Phase III clinical trial for Alzheimer’s disease treatment failed to show any benefit. [1]Latrepirdine operates through multiple mechanisms of action, blocking the action of neurotoxic beta-amyloid proteins, inhibiting L-type calcium channels, modulating the action of AMPA and NMDA glutamate receptors, exerting a neuroprotective effect by blocking a novel target that involves mitochondrial pores, blocking a number of other receptors including α-adrenergic, 5-HT2C, 5-HT5A, and 5-HT6. [1] |